1Ondetti MA,Rubin B,Cushman DW.Design of specific inhibitors of angiotensin-converting enzyme: new class of orally active antihypertensive agents. Science . 1977
2Desai,B.G,Annamalai,A.R,Divya,B,Dinesh,B.M.Effect of en-hancers on permeation kinetics of captopril for transdermal system. Asian Journal of Pharmaceutics . 2008
3Carlene M,Derrick A,Valery L,et al.B100d pressure and stroke:an overview of published reviews[J].Stroke,2004,35:1024-1033.
4The Allhat officers and coordinators for the Allhat collaborative research group.Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker versus diuretic:the Antihypertensive and lipid lowering treatmeat to prevent Heart Attack Trial(ALLHAT)[J].JAMA,2002,288(23):2981-2997.
5Brown MJ,Palmer CR,Castaigne A,et al.Morbidity and mortality in patients randomised to double-blind treatment with a longacting calcium channel blocker or diuretic in the International Nifedipine GITS study Intervention as a goal in hypertension treatmeat(INSIGHT)[J].Lancent,2000,356(9227):366-372.
6Poulter NR,Wedel H,Dahlof B,et al.Role of blood pressure and other variables in the differential cardiovascular event rates noted in the anglo-scandinavian cardiac outcomes trial-klood pressure lowering arm(ASCOT-BPLA)[J].Lancent,2005,366:907-913.
7Hansson L,Zanchetti A,Carruthers G,et al.Principal effects of intensive blood-pressure lowering and low-dose asirin in patients with hypertension:principal results of the hypertension optimal treatment(HOT) randomized trial[J].Lancet,1998,351:1755-1762.
8Liu L,Zhang Y,Liu G,et al.The Felodipine even reduction(FEVER) study:a randomized long-term plcebo-controlled trial in Chinese hypertensive patients[J].J Hypertension,2005,23:2157-2172.
10Chen X,Zhou ZW,Xm CC,et al.Role of P-glycoprotcin inrestricting the brain penetration of tanshinone ITA,a major active constituont from the root of salvia miltiorrhiza bunge,aeros the blood-brain baltigl[J].Xenobiofica,2007,37(6):635-678.
